Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow mononuclear cells + umbilical cord-derived mesenchymal stem cells
- Development stage
- Preclinical
- Lead developer
- ReeLabs
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Injection
01
Overview
This therapy is a **combination stem cell therapy** being developed by **ReeLabs** for **Duchenne Muscular Dystrophy**. It combines **autologous bone marrow mononuclear cells** with **allogeneic umbilical cord-derived mesenchymal stem cells** and was described in an Indian clinical program in which patients received one session of autologous BM-MNCs followed by three sessions of UC-MSCs. The therapeutic rationale is to pair the regenerative and trophic paracrine activity of bone marrow mononuclear cells with the immunomodulatory, anti-inflammatory, and tissue-repair properties of umbilical cord-derived mesenchymal stem cells in an effort to support muscle regeneration and functional stabilization in dystrophin-deficient muscle. No discrete molecular target, brand name, or standard development code appears to have been assigned.
- Other names
- autologous BM-MNCs + UC-MSCscombination stem cell therapyautologous bone marrow-derived mononuclear cells + umbilical cord-derived mesenchymal stem cells
Beyond the preview
Go deeper on autologous bone marrow mononuclear cells + umbilical cord-derived mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow mononuclear cells + umbilical cord-derived mesenchymal stem cells.